BLOC1S1 and amyotrophic lateral sclerosis: Therapeutic strategies will be developed to engineer bifunctional compounds that either enhance BLOC1S1‐TDP‐43 binding to combat intracellular pathogens like Brucella or disrupt this interaction to restore nuclear TDP‐43 function in ALS/FTD models.